Business Segments · Research and development expense
Medical Essentials — Research and development expense
Becton, Dickinson and Company Medical Essentials — Research and development expense increased by 12.8% to $53M in Q1 2026 compared to the prior quarter.
Analysis
StatementSegment
CategoryGrowth
SignalContext dependent
VolatilityModerate
First reportedQ1 2025
Last reportedQ2 2026May 7, 2026
Rolls up toR&D
How to read this metric
Higher spending indicates a focus on innovation and future product pipelines, while lower spending may suggest a focus on cost optimization or a mature product lifecycle.
Detailed definition
This metric captures the investment made by the Medical Essentials segment into research and development activities, inc...
Peer comparison
Comparable to R&D investment levels in mature medical device product lines.
Metric ID:
bdx_segment_medical_essentials_research_and_development_expenseHistorical Data
4 periods
| Q1 '25 | Q2 '25 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|
| Value | $44M | $48M | $47M | $53M |
| QoQ Change | — | +9.1% | -2.1% | +12.8% |
| YoY Change | — | — | +6.8% | +10.4% |
Range$44M – $53M
Avg YoY Growth+8.6%
Median YoY Growth+8.6%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Becton, Dickinson and Company's medical essentials — research and development expense?
- Becton, Dickinson and Company (BDX) reported medical essentials — research and development expense of $53M in Q1 2026.
- What does medical essentials — research and development expense mean?
- The amount spent on research and development for the Medical Essentials segment.